The SafeBridge team interviewed the chemists to determine when they were exposed, what they were doing before and after the exposure, and what substances they had encountered in performing their work. The team hired a third-party testing company to perform a toxicological investigation of the synthesized compounds used in the project. The only compound to show high chloracnegenic activity in the assay was triazoloquinoxaline, a novel compound used as a synthetic intermediate in the project.

Once the diagnosis of chloracne was confirmed, the European occupational health department initiated a detailed assessment of the exposure risks at the lab. Two of the chemists were treated with an oral antibiotic, two received topical therapy only, and three required no treatment at all. The patients were then scheduled for regular health assessments at 6- and 12-month intervals. Over the next three months, the laboratory was cleared by destroying or removing lab equipment through an exterior window to protect further internal corridors or offices from becoming contaminated.